Skip to main content

Afamelanotide Evaluated as Skin DNA Repair Therapy in Healthy Volunteers

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Clinuvel Pharmaceuticals
Clinuvel PharmaceuticalsAustralia - Melbourne
1 program
1
AfamelanotidePhase 1Peptide1 trial
Active Trials
NCT05368857Completed10Est. Feb 2023

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Clinuvel PharmaceuticalsAfamelanotide

Clinical Trials (1)

Total enrollment: 10 patients across 1 trials

DNA Repair Capacity of Afamelanotide on Ultraviolet Radiation-induced DNA Damage in Healthy Volunteers

Start: Jan 2022Est. completion: Feb 202310 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.